LOS ANGELES, CA - June 23, 2026 (NEWMEDIAWIRE) - HeartBeam (NASDAQ: BEAT) has launched a new pilot study designed to evaluate its proprietary on-demand 12-lead ECG patch in detecting coronary artery disease and ischemia, a condition where blood flow and oxygen supply to tissue are inadequate. The study marks a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (“MCT”) markets.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam's technology aims to fill a critical gap. “Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG could provide clinicians with the data needed to detect ischemia earlier and more conveniently than current methods.”
The pilot study will focus on evaluating the patch's ability to capture high-quality ECG signals on demand, which is a key requirement for detecting ischemia. Unlike traditional continuous monitors that record heart rhythms over time, the HeartBeam patch allows patients to record a 12-lead ECG at the moment symptoms occur, potentially capturing critical information that might otherwise be missed. This approach could reduce the need for multiple clinic visits and enable more timely interventions.
The implications of this study are significant for the management of coronary artery disease. If successful, the HeartBeam patch could become a valuable tool for remote patient monitoring, allowing healthcare providers to assess cardiac function in real-time without requiring patients to be tethered to a clinic. This could lead to earlier detection of ischemia, reduced hospitalizations, and improved outcomes for the millions of people living with coronary artery disease. The patch is designed for long-term use, providing continuous monitoring capabilities that could replace traditional Holter monitors and event recorders.
HeartBeam's technology is part of a broader trend toward miniaturized, patient-centric cardiac monitoring devices. The company's focus on on-demand 12-lead ECG generation addresses a key limitation of existing patch-based monitors, which typically only record heart rate and rhythm, not the detailed electrical activity needed to detect ischemia. By enabling patients to record a full 12-lead ECG at home, the HeartBeam patch could democratize access to advanced cardiac diagnostics.
For more information on the study and HeartBeam's technology, refer to the company's newsroom at https://ibn.fm/BEAT. Full terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
Forward-looking statements in this article are subject to risks and uncertainties, as detailed in the company's filings with the SEC.
